The presence of broadly neutralizing anti-SARS-CoV-2 RBD antibodies elicited by primary series and booster dose of COVID-19 vaccine
PLOS Pathogens · 2024
DOI: 10.1371/journal.ppat.1012246 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2024. Verfasst von Xiaorui Chen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Genomics Research Center, Academia Sinica, Taipei, Taiwan. Hauptthemen laut MEDLINE: SARS-CoV-2, Antibodies, Viral, COVID-19, COVID-19 Vaccines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council of Taiwan, National Taiwan University, National Science and Technology Council.
Abstract (Originalsprache)
Antibody-mediated immunity plays a key role in protection against SARS-CoV-2. We characterized B-cell-derived anti-SARS-CoV-2 RBD antibody repertoires from vaccinated and infected individuals and elucidate the mechanism of action of broadly neutralizing antibodies and dissect antibodies at the epitope level. The breadth and clonality of anti-RBD B cell response varies among individuals. The majority of neutralizing antibody clones lose or exhibit reduced activities against Beta, Delta, and Omicron variants. Nevertheless, a portion of anti-RBD antibody clones that develops after a primary series or booster dose of COVID-19 vaccination exhibit broad neutralization against emerging Omicron BA.2, BA.4, BA.5, BQ.1.1, XBB.1.5 and XBB.1.16 variants. These broadly neutralizing antibodies share genetic features including a conserved usage of the IGHV3-53 and 3–9 genes and recognize three clustered epitopes of the RBD, including epitopes that partially overlap the classically defined set identified early in the pandemic. The Fab-RBD crystal and Fab-Spike complex structures corroborate the epitope grouping of antibodies and reveal the detailed binding mode of broadly neutralizing antibodies. Structure-guided mutagenesis improves binding and neutralization potency of antibody with Omicron variants via a single amino-substitution. Together, these results provide an immunological basis for partial protection against severe COVID-19 by the ancestral strain-based vaccine and indicate guidance for next generation monoclonal antibody development and vaccine design.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Genomics Research Center, Academia Sinica, Taipei, Taiwan.
- Chemical Biology and Molecular Biophysics program, Taiwan International Graduate Program, Academia Sinica, Taipei, Taiwan.
- Institute of Biochemical Sciences, National Taiwan University, Taipei, Taiwan.
- MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom.
- Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, United Kingdom.
- Department of Infectious Diseases, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, and Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
ORCID-Profile: Kuan-Ying A Huang
Förderung
- National Science and Technology Council of Taiwan
- National Taiwan University
- National Science and Technology Council
- Genomics Research Center, Summit Project and the Translational Medical Research Program, Academia Sinica and Taiwan Bio-Development Foundation
Zitieren
APA
Chen, X., Mohapatra, A., Nguyen, H. T. V., Schimanski, L., Kit Tan, T., Rijal, P., Chen, C. P., Cheng, S. H., Lee, W. H., Chou, Y. C., Townsend, A. R., Ma, C., & Huang, K. A. (2024). The presence of broadly neutralizing anti-SARS-CoV-2 RBD antibodies elicited by primary series and booster dose of COVID-19 vaccine. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1012246
Vancouver
Chen X, Mohapatra A, Nguyen HTV, Schimanski L, Kit Tan T, Rijal P, et al. The presence of broadly neutralizing anti-SARS-CoV-2 RBD antibodies elicited by primary series and booster dose of COVID-19 vaccine. PLOS Pathogens. 2024. doi:10.1371/journal.ppat.1012246
BibTeX
@article{Chen2024,
author = {Chen, Xiaorui and Mohapatra, Arpita and Nguyen, Hong Thuy Vy and Schimanski, Lisa and Kit Tan, Tiong and Rijal, Pramila and Chen, Cheng-Pin and Cheng, Shu-Hsing and Lee, Wen-Hsin and Chou, Yu-Chi and Townsend, Alain R and Ma, Che and Huang, Kuan-Ying A},
title = {The presence of broadly neutralizing anti-SARS-CoV-2 RBD antibodies elicited by primary series and booster dose of COVID-19 vaccine},
journal = {PLOS Pathogens},
year = {2024},
doi = {10.1371/journal.ppat.1012246}
}
EUVIMED